TY - JOUR
T1 - Overcoming Barriers to Adopting and Implementing Pharmacotherapy
T2 - the Medication Research Partnership
AU - Croff, Raina
AU - Hoffman, Kim
AU - Alanis-Hirsch, Kelly
AU - Ford, Jay
AU - McCarty, Dennis
AU - Schmidt, Laura
N1 - Funding Information:
An award from the National Institute on Drug Abuse (R01-DA029716) supported the study design, implementation, and analysis. We would like to thank our participating providers: Bowling Green Brandywine (Lisa Olander), Eagleville Hospital (Charlie Folks), Horsham Clinic (Billie-Jo Sellman), Livengrin Foundation (Charlie Wolfe); Mirmont Treatment Centers (Pam Fries-Coffey); Maryland Treatment Centers (Meghan Westwood); Pace (Bruce Johnson); Penn Foundation (Christopher Squillaro, DO); and White Deer Run Allenwood (Amber Dissinger and Kieran Pelletier). In addition, we would like to thank Aetna (Dr. Hyong Un, Danielle Yemm, Bruce D Condit, and Dawn R Keiser) for their support in the development and implementation of the project. Finally, we would like to thank Dr. Kimberly A Johnson who was an active member of the research team.
PY - 2019/4/15
Y1 - 2019/4/15
N2 - Pharmacotherapy includes a growing number of clinically effective medications for substance use disorder, yet there are significant barriers to its adoption and implementation in routine clinical practice. The Medication Research Partnership (MRP) was a successful effort to promote adoption of pharmacotherapy for opioid and alcohol use disorders in nine substance abuse treatment centers and a commercial health plan. This qualitative analysis of interviews (n = 39) conducted with change leaders at baseline and at the end/beginning of 6-month change cycles explains how treatment centers overcame obstacles to the adoption, implementation, and sustainability of pharmacotherapy. Results show that barriers to adopting, implementing, and sustaining pharmacotherapy can be overcome through incremental testing of organizational change strategies, accompanied by expert coaching and a learning community of like-minded professionals. The greatest challenges lie in overcoming abstinence-only philosophies, establishing a business case for pharmacotherapy, and working with payers and pharmaceutical representatives.
AB - Pharmacotherapy includes a growing number of clinically effective medications for substance use disorder, yet there are significant barriers to its adoption and implementation in routine clinical practice. The Medication Research Partnership (MRP) was a successful effort to promote adoption of pharmacotherapy for opioid and alcohol use disorders in nine substance abuse treatment centers and a commercial health plan. This qualitative analysis of interviews (n = 39) conducted with change leaders at baseline and at the end/beginning of 6-month change cycles explains how treatment centers overcame obstacles to the adoption, implementation, and sustainability of pharmacotherapy. Results show that barriers to adopting, implementing, and sustaining pharmacotherapy can be overcome through incremental testing of organizational change strategies, accompanied by expert coaching and a learning community of like-minded professionals. The greatest challenges lie in overcoming abstinence-only philosophies, establishing a business case for pharmacotherapy, and working with payers and pharmaceutical representatives.
UR - http://www.scopus.com/inward/record.url?scp=85047662261&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85047662261&partnerID=8YFLogxK
U2 - 10.1007/s11414-018-9616-9
DO - 10.1007/s11414-018-9616-9
M3 - Article
C2 - 29845513
AN - SCOPUS:85047662261
VL - 46
SP - 330
EP - 339
JO - Journal of Behavioral Health Services and Research
JF - Journal of Behavioral Health Services and Research
SN - 1094-3412
IS - 2
ER -